EA Pharma Co. Ltd. wish to engage research that fulfils at least one of four requirements:
1. The discovery of drug candidates that improve the symptoms of NASH
Our client seeks to identify drug candidates that can improve Non-alcoholic fatty liver disease Activity Score (NAS) (i.e., hepatocellular fatty change, infiltration of inflammatory cells, and hepatocellular ballooning) and inhibit the progression of liver fibrosis. Priorities will be given to drug candidates fulfilling one or more of the criteria below:
Technology
Academic Researcher
Centre of Excellence
Research Project
Spinout Company
Technology
Academic Researcher
Centre of Excellence
Research Project
Spinout Company
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.